Skip to main content

Regulatory and Washington

  • Personal Care Products Council supports expanded FDA role in industry oversight

    WASHINGTON The Personal Care Products Council announced on July 15 that it is calling for a greater role by the Food and Drug Administration in regulatory oversight of personal care products and assessing ingredient safety.

    The announcement came less than a week before the introduction of the Safe Cosmetics Act of 2010 in Congress by Reps. Jan Schakowsky, D-Ill., Ed Markey, D-Mass., and Tammy Baldwin, D-Wis.

  • Mylan's generic arthritis drug receives FDA approval

    PITTSBURGH The Food and Drug Administration has approved a generic arthritis treatment made by Mylan, the drug maker said Wednesday.

     

    The FDA approved nabumetone tablets, a treatment for osteoarthritis and rheumatoid arthritis, in the 500 mg and 750-mg strengths.

     

     

  • Watson seeks FDA approval for generic Renvela, confirms patent challenge

    MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals hopes to be the first to market a version of a kidney disease treatment made by Genzyme, Watson said Monday.

    Watson said it filed a regulatory approval application with the Food and Drug Administration for sevelamer carbonate for oral suspension. The drug is a generic version of Genzyme’s Renvela, used to control serum phosphorus in patients with chronic kidney disease who are on dialysis.

     

  • Report, PCPC sniff out truth on fragrances’ safety

    WASHINGTON —A new report by activist group Campaign for Safe Cosmetics alleging that a number of popular brand-name perfumes and teen body sprays have “secret” chemicals that could be harmful to consumers is “erroneous” and “does a disservice to consumers,” stated John Bailey, chief scientist of the Personal Care Products Council, in response to the claim.

X
This ad will auto-close in 10 seconds